Healthcare - Biotechnology - NASDAQ - US
$ 0.7551
-4.48 %
$ 90.2 M
Market Cap
-0.42
P/E
CASH FLOW STATEMENT
-173 M
OPERATING CASH FLOW
281 M
INVESTING CASH FLOW
1.04 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Invivyd, Inc.
| Net Income | -199 M |
| Depreciation & Amortization | 2.03 M |
| Capital Expenditures | -615 K |
| Stock-Based Compensation | 18.7 M |
| Change in Working Capital | 5.89 M |
| Others | -1.7 M |
| Free Cash Flow | -174 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (198.6) | (241.3) | (226.8) | (65.3) |
| Depreciation & Amortization | 2.0 | 0.5 | 1 K | 0 |
| Deferred Income Tax | 0 | 0 | 1.4 | 0 |
| Stock Based Compensation | 18.7 | 21.6 K | 17.8 K | 266 |
| Other Operating Activities | (1.1) | 15.3 | 66 K | 40.1 |
| Change in Working Capital | 5.9 | (16.1) | 22.8 | 10.7 |
| Cash From Operations | (173.2) | (220.0) | (184.7) | (14.6) |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | (0.6) | (1.7) | 84 K | 0 |
| Other Items | 281.3 | (229.0) | (50.6) | 0 |
| Cash From Investing Activities | 280.7 | (230.7) | (50.7) | 0 |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | 1 K | 4 K | 0 | 3 K |
| Total Debt Repaid | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.0 | 0.5 | 331.8 | 129.6 |
| Cash From Financing Activities | 1.0 | 0.5 | 662.7 | 129.6 |
| CHANGE IN CASH | ||||
| Net Change In Cash | 108.6 | (450.1) | 427.2 | 115.0 |
| FREE CASH FLOW | ||||
| Free Cash Flow | (173.8) | (221.7) | (184.8) | (14.6) |